Company / Cash & Equivalents
Enovis Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$36.4M
FY2025
5-year range
$24.3M / $680.3M
FY2021-FY2025
Trend
-24.5%
vs FY2024
Sector context
#135 of 148
Health Care
What the data says
Among 148 Health Care companies, Enovis is in the bottom 9% for cash & equivalents. Cash & Equivalents has fluctuated over the past 10 years, ranging from $24M in FY2022 to $680M in FY2021.
Based on SEC 10-K filings.
$36M in FY2025 with a 5-year CAGR of -17.8%.
Remained stable around $36M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +14.4%
- 5-Year CAGR
- -17.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 148This company $36.4M Sector average $1.2B
▼
-96.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -17.8%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 24.5% year-over-year.
- Ranks #135 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $36.4M | -24.5% |
| FY2024 | $48.2M | +33.1% |
| FY2023 | $36.2M | +49.0% |
| FY2022 | $24.3M | -96.4% |
| FY2021 | $680.3M | +600.8% |
| FY2020 | $97.1M | -11.5% |
| FY2019 | $109.6M | +42.1% |
| FY2018 | $77.2M | -70.6% |
| FY2017 | $262.0M | +25.5% |
| FY2016 | $208.8M | -32.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026